TARAProtara Therapeutics, Inc.

TARA Stock Price, Valuation & Chart | Protara Therapeutics, Inc.

Compare

$3.940+0.04 (+1.03%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology TARA intrinsic value TARA calculated fair value vs price

Overview Financials Dividends Ratios

TARA Historical price chart

TARA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization221.44M

PE Ratio-2.94

EPS-1.34

Trading Volume335.38K

Today's High/Low4.01/3.85

Dividend Yield0.00

52 Week High/Low7.82/3.02

Shares Outstanding56.20M

TARA Financial Statement

TARA Analyst ratings

TARA Analysis & performance metrics

TARA Company profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare…

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid…

TARA Management team

Name

Position

Leonardo Viana Nicacio M.D.

Chief Medical Officer

Hannah Fry

Vice President, Principal Accounting Officer & Controller

Patrick Fabbio M.B.A.CFO

Chief Financial Officer

Shane Williams Ph.D.

Chief People Officer

Jesse SheffermanCEO

Co-founder, Chief Executive Officer, President & Director

Jacqueline Zummo M.B.A., M.P.H., Ph.D.

Co-Founder & Chief Scientific Operations Officer

Justine O'Malley

Senior Vice President of Investor Relations & Corporate Affairs

Mary J. Grendell J.D.

General Counsel & Corporate Secretary

Name

Position

Leonardo Viana Nicacio M.D.

Chief Medical Officer

Hannah Fry

Vice President, Principal Accounting Officer & Controller

Patrick Fabbio M.B.A.CFO

Chief Financial Officer

Shane Williams Ph.D.

Chief People Officer

Jesse SheffermanCEO

Co-founder, Chief Executive Officer, President & Director

Jacqueline Zummo M.B.A., M.P.H., Ph.D.

Co-Founder & Chief Scientific Operations Officer

Justine O'Malley

Senior Vice President of Investor Relations & Corporate Affairs

Mary J. Grendell J.D.

General Counsel & Corporate Secretary

Management Team

Leonardo Viana Nicacio M.D.

Chief Medical Officer

Hannah Fry

Vice President, Principal Accounting Officer & Controller

Patrick Fabbio M.B.A.CFO

Chief Financial Officer

Shane Williams Ph.D.

Chief People Officer

Jesse SheffermanCEO

Co-founder, Chief Executive Officer, President & Director

Jacqueline Zummo M.B.A., M.P.H., Ph.D.

Co-Founder & Chief Scientific Operations Officer

Justine O'Malley

Senior Vice President of Investor Relations & Corporate Affairs

Mary J. Grendell J.D.

General Counsel & Corporate Secretary

Management

Leonardo Viana Nicacio M.D.

Chief Medical Officer

Hannah Fry

Vice President, Principal Accounting Officer & Controller

Patrick Fabbio M.B.A.CFO

Chief Financial Officer

Shane Williams Ph.D.

Chief People Officer

Jesse SheffermanCEO

Co-founder, Chief Executive Officer, President & Director

Jacqueline Zummo M.B.A., M.P.H., Ph.D.

Co-Founder & Chief Scientific Operations Officer

Justine O'Malley

Senior Vice President of Investor Relations & Corporate Affairs

Mary J. Grendell J.D.

General Counsel & Corporate Secretary

Total 8 executives

TARA Frequently asked questions

What is Protara Therapeutics, Inc. (TARA) Stock Price?

Current stock price of Protara Therapeutics, Inc. (TARA) stock is $3.940. The stock price is +1.03% higher in the session. The intraday range can be seen from this page. Volume of Protara Therapeutics, Inc. (TARA) stock is 335.38K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Protara Therapeutics, Inc. (TARA) stock price going up or down today?

The stock price of Protara Therapeutics, Inc. (TARA) can change with earnings, company news, and overall market sentiment. Protara Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Protara Therapeutics, Inc. stock expensive at its current price?

Whether Protara Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TARA on this page is -2.94. EPS on this page is -1.34. Compare those figures with peers and growth expectations before deciding if the current Protara Therapeutics, Inc. price is justified.

How has the stock price of Protara Therapeutics, Inc. (TARA) performed historically?

Historical performance for Protara Therapeutics, Inc. (TARA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TARA reacted to past earnings and market events.

Should I buy Protara Therapeutics, Inc. (TARA) stock, at this price?

Buying Protara Therapeutics, Inc. (TARA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.